Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.

ABSTRACT:

Background

Treatment with anti-PD1 monoclonal antibodies improves the survival of metastatic melanoma patients but only a subgroup of patients benefits from durable disease control. Predictive biomarkers for durable benefit could improve the clinical management of patients.

Methods

Plasma samples were collected from patients receiving anti-PD1 therapy for ctDNA quantitative assessment of BRAF^V600 and NRAS^Q61/G12/G13 mutations.

Results

After a median follow-up of 84 weeks 457 samples from 85 patients were analyzed. Patients with undetectable ctDNA at baseline had a better PFS (Hazard ratio (HR) = 0.47, median 26 weeks versus 9 weeks, p = 0.01) and OS (HR = 0.37, median not reached versus 21.3 weeks, p = 0.005) than patients with detectable ctDNA.

SUBMITTER: Seremet T 

PROVIDER: S-EPMC6727487 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature